Page 1 | Search Results | Blood | American Society of Hematology

1-19 of 19

Sort by

Sort Order Select

Journal Articles

Comparison of Outcomes in Chronic Lymphocytic Leukemia (CLL) with the Addition of Rituximab to Initial Treatment: A Comparative Effectiveness Analysis in the Province of British Columbia (BC), Canada

Lauren J. Lee, MD, Alina S. Gerrie, MD FRCPC, Helene Bruyere, MD FCCMG, Tanya L. Gillan, PhD FCCMG, Stephen J.T. Huang, BMLSc, Cynthia L. Toze, MD FRCPC, Khaled M. Ramadan, MBBCh, MRCPI, FRCPath, FRCP, FRCPC

Blood (2014) 124 (21): 3344.

https://doi.org/10.1182/blood.V124.21.3344.3344

Published: 2014

Journal Articles

Autoimmune Cytopenia in Chronic Lymphocytic Leukemia: Effect on Outcome and Survival, a Population Based Analysis in British Columbia, Canada

Alaa A Alzaki, MBBS, Alina S Gerrie, MD, Tanya L. Gillan, PhD FCCMG, Steven Huang, Miriam Ahmed, Cynthia L. Toze, MD FRCPC, Heather A Leitch, MD PhD, Khaled M Ramadan, MB

Blood (2014) 124 (21): 1945.

https://doi.org/10.1182/blood.V124.21.1945.1945

Published: 2014

Journal Articles

Clonal Evolution Predicts Poor Prognosis in Chronic Lymphocytic Leukaemia and Is Possibly a Worse Prognostic Factor Than 17p Deletion: A Population Based Cohort study of FISH Testing in British Columbia, Canada

Krystal Bergin, MBBS, Alina S. Gerrie, MD, FRCPC, Steven J.T. Huang, BMLSc, Khaled M Ramadan, MBBCH, MRCPI, FRCPath, FRCP, FRCPC, Aly Karsan, MD, Monica Anne Hrynchak, MD, FRCP(C), Chinmay B. Dalal, MD, Helene Bruyere, MD, FCCMG, Adam C. Smith, PhD, FCCMG, FACMG, Cynthia L. Toze, MD, MHSc, FRCPC, Tanya L. Gillan, PhD, FCCMG

Blood (2012) 120 (21): 1401.

https://doi.org/10.1182/blood.V120.21.1401.1401

Published: 2012

Journal Articles

Comprehensive Assessment of Clinical Outcomes for CLL Patients with Trisomy 12 (+12): Results of a Population-Based Analysis of 822 CLL Patients in British Columbia (BC), Canada

Alina S. Gerrie, MD, FRCPC, MPH, Steven J.T. Huang, BMLSc, Helene Bruyere, MD, FCCMG, Chinmay B. Dalal, MD, Monica Anne Hrynchak, MD, FRCP(C), Aly Karsan, MD, Khaled M Ramadan, MBBCH, MRCPI, FRCPath, FRCP, FRCPC, Adam C. Smith, PhD, FCCMG, FACMG, Tanya L. Gillan, PhD, FCCMG, Cynthia L. Toze, MD, FRCP(C)

Blood (2012) 120 (21): 3897.

https://doi.org/10.1182/blood.V120.21.3897.3897

Published: 2012

Journal Articles

Improved Survival with Iron Chelation Therapy for Lower IPSS Risk MDS Appears to Have a Stronger Association in Patients with a Non-RARS Diagnosis

Heather A Leitch, MD, PhD, FRCPC, Christopher Chan, Chantal S Leger, MD, FRCP(C), Lynda M Foltz, MD, FRCP(C), Khaled M Ramadan, MBBCH, MRCPI, FRCPath, FRCP, FRCPC, Linda M Vickars, MD, FRCP(C)

Blood (2011) 118 (21): 1732.

https://doi.org/10.1182/blood.V118.21.1732.1732

Published: 2011

Journal Articles

Fludarabine (F) and Rituximab (R) (FR) as Initial Therapy for Symptomatic Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL): Population-Based Experience Matches Clinical Trials.

Alina S. Gerrie, MD, FRCPC, Cynthia L. Toze, MD, FRCP(C), Khaled M. Ramadan, MB, Charles H. Li, MD, Adrian Yee, MD, FRCPC, Joseph M. Connors, MD

Blood (2009) 114 (22): 2363.

https://doi.org/10.1182/blood.V114.22.2363.2363

Published: 2009

Journal Articles

Autologous Stem Cell Transplantation Is Superior to Myeloablative Allogeneic SCT as a Salvage Therapy for Patients with Refractory/Relapsed Transformed Lymphoma

Blood (2008) 112 (11): 4459.

https://doi.org/10.1182/blood.V112.11.4459.4459

Published: 2008

Journal Articles

A Scoring System Based on Clinical, Blood Count and Immunophenotypic Data Can Predict the Risk of Disease Progression in Patients with Chronic Lymphocytic Leukemia

Sina Alipour, BSc, Heather Leitch, MD, PhD, Linda M Vickars, MD, Lynda M Foltz, MD, Paul F Galbraith, MD, Chantal S Leger, MD, Khaled M Ramadan, MBBCh, FRCPI, FRCPath

Blood (2008) 112 (11): 4185.

https://doi.org/10.1182/blood.V112.11.4185.4185

Published: 2008

Journal Articles

CD38 Expression above 20% Predicts Disease Progression in Chronic Lymphocytic Leukemia and Is a Useful Prognostic Marker Where Cytogenetic and Molecular Markers Are Not Available

Sina Alipour, BSc, Heather Leitch, MD, PhD, Linda M Vickars, MD, Lynda M Foltz, MD, Paul F Galbraith, MD, Chantal S Leger, MD, Khaled M Ramadan, MBBCh, FRCPI, FRCPath

Blood (2008) 112 (11): 4190.

https://doi.org/10.1182/blood.V112.11.4190.4190

Published: 2008

Journal Articles

Richter Transformation of Chronic Lymphocytic Leukemia: Incidence, Risk Factors and Outcome

Sina Alipour, BSc, Heather Leitch, MD, PhD, Linda M Vickars, MD, Lynda M Foltz, MD, Paul F Galbraith, MD, Chantal S Leger, MD, Khaled M Ramadan, MBBCh, FRCPI, FRCPath

Blood (2008) 112 (11): 3179.

https://doi.org/10.1182/blood.V112.11.3179.3179

Published: 2008

Journal Articles

Comparison of Outcome Between Refractory/Relapsed De Novo Diffuse Large B-Cell and Transformed Lymphoma Using Related and Unrelated Allogeneic Hematopoietic SCT.

Blood (2008) 112 (11): 2173.

https://doi.org/10.1182/blood.V112.11.2173.2173

Published: 2008

Journal Articles

Salvage Therapy with Allogeneic Stem Cell Transplantation Results in Better Outcome for Patients with Relapsed/Refractory Follicular Lymphoma Compared to Those with Transformed Non-Hodgkin Lymphoma: A Population-Based Comparative Study.

Blood (2008) 112 (11): 975.

https://doi.org/10.1182/blood.V112.11.975.975

Published: 2008

Journal Articles

Improved Survival in Red Blood Cell Transfusion Dependent Patients with Primary Myelofibrosis (PMF) Receiving Iron Chelation Therapy.

Heather Leitch, MD, PhD, Hatoon Ezzat, MBBS, Meaghan D Rollins, BHK, Trisha A Goodman, BHK, Chantal S Leger, MD, Dominic HC Wong, BSc, Khaled M Ramadan, MB, Lynda M Foltz, MD, Linda M Vickars, MD

Blood (2008) 112 (11): 1748.

https://doi.org/10.1182/blood.V112.11.1748.1748

Published: 2008

Journal Articles

Improved Leukemia-Free and Overall Survival in Patients with Myelodysplastic Syndrome Receiving Iron Chelation Therapy: A Subgroup Analysis.

Heather A. Leitch, MD, PhD, Dominic H.C. Wong, Chantal S. Leger, MD, Khaled M. Ramadan, MD, Meaghan D. Rollins, BHK, Michael J. Barnett, MB, Trisha A. Goodman, BHK, Karen K. Wong, Paul F. Galbraith, MD, Linda M. Vickars, MD

Blood (2007) 110 (11): 1469.

https://doi.org/10.1182/blood.V110.11.1469.1469

Published: 2007

Journal Articles

Transfusion Dependence in Patients with Primary Myelofibrosis Has a Negative Impact on Survival Independent of Decreased Myelopoiesis.

Heather A. Leitch, MD, PhD, Hatoon Ezzat, MD, Meaghan D. Rollins, BHK, Dominic H.C. Wong, Chantal S. Leger, MD, Khaled M. Ramadan, MD, Michael J. Barnett, MB, Linda M. Vickars, MD

Blood (2007) 110 (11): 4653.

https://doi.org/10.1182/blood.V110.11.4653.4653

Published: 2007

Journal Articles

Myeloablative Allogeneic Stem Cell Transplantation for Relapsed Composite Low and Intermediate Grade Lymphoma Is Not Superior to Autologous Stem Cell Transplantation - Reduced Relapse Risk Is Offset by Higher Treatment Related Mortality.

Khaled M. Ramadan, Joseph M. Connors, Abdulwahab J. Al-Tourah, Randy D. Gascoyne, Kevin Song, Michael J. Barnett, Stephen H. Nantel, Thomas J. Nevill, John D. Shepherd, Heather J. Sutherland, Julye Lavoie, Donna L. Forrest, Donna E. Hogge, Nicholas J. Voss, Clayton A. Smith, Cynthia L. Toze

Blood (2006) 108 (11): 3039.

https://doi.org/10.1182/blood.V108.11.3039.3039

Published: 2006

Journal Articles

Long Term Results of Myeloablative Allogeneic Stem Cell Transplantation Using Related and Unrelated Donors in Patients with Relapsed Composite Low and Intermediate Grade (Including Transformed) Lymphoma.

Khaled M. Ramadan, Joseph M. Connors, Randy D. Gascoyne, Kevin Song, Michael J. Barnett, Stephen H. Nantel, Thomas J. Nevill, John D. Shepherd, Heather J. Sutherland, Julye Lavoie, Donna L. Forrest, Donna E. Hogge, Nicholas J. Voss, Ryan Brinkman, Clayton A. Smith, Cynthia L. Toze

Blood (2006) 108 (11): 3139.

https://doi.org/10.1182/blood.V108.11.3139.3139

Published: 2006

Journal Articles

Prior Rituximab Reduces Relapse and Improves Survival Following High Dose Chemotherapy and Stem Cell Transplantation for Relapsed Composite Low and Intermediate Grade (Including Transformed) Lymphoma.

Blood (2006) 108 (11): 3662.

https://doi.org/10.1182/blood.V108.11.3662.3662

Published: 2006

Journal Articles

Long Term Follow-Up Results for Patients with Hodgkin Lymphoma after First Remission of Longer Than Ten Years: A Population Based Study of 954 Patients from the British Columbia Cancer Agency.

Khaled M. Ramadan, MBBCh, MRCPI, MRCPat, Joseph M. Connors, MD

Blood (2006) 108 (11): 2269.

https://doi.org/10.1182/blood.V108.11.2269.2269

Published: 2006

NARROW

Comparison of Outcomes in Chronic Lymphocytic Leukemia (CLL) with the Addition of Rituximab to Initial Treatment: A Comparative Effectiveness Analysis in the Province of British Columbia (BC), Canada

Autoimmune Cytopenia in Chronic Lymphocytic Leukemia: Effect on Outcome and Survival, a Population Based Analysis in British Columbia, Canada

Clonal Evolution Predicts Poor Prognosis in Chronic Lymphocytic Leukaemia and Is Possibly a Worse Prognostic Factor Than 17p Deletion: A Population Based Cohort study of FISH Testing in British Columbia, Canada

Comprehensive Assessment of Clinical Outcomes for CLL Patients with Trisomy 12 (+12): Results of a Population-Based Analysis of 822 CLL Patients in British Columbia (BC), Canada

Improved Survival with Iron Chelation Therapy for Lower IPSS Risk MDS Appears to Have a Stronger Association in Patients with a Non-RARS Diagnosis

Fludarabine (F) and Rituximab (R) (FR) as Initial Therapy for Symptomatic Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL): Population-Based Experience Matches Clinical Trials.

Autologous Stem Cell Transplantation Is Superior to Myeloablative Allogeneic SCT as a Salvage Therapy for Patients with Refractory/Relapsed Transformed Lymphoma

A Scoring System Based on Clinical, Blood Count and Immunophenotypic Data Can Predict the Risk of Disease Progression in Patients with Chronic Lymphocytic Leukemia

CD38 Expression above 20% Predicts Disease Progression in Chronic Lymphocytic Leukemia and Is a Useful Prognostic Marker Where Cytogenetic and Molecular Markers Are Not Available

Richter Transformation of Chronic Lymphocytic Leukemia: Incidence, Risk Factors and Outcome

Comparison of Outcome Between Refractory/Relapsed De Novo Diffuse Large B-Cell and Transformed Lymphoma Using Related and Unrelated Allogeneic Hematopoietic SCT.

Salvage Therapy with Allogeneic Stem Cell Transplantation Results in Better Outcome for Patients with Relapsed/Refractory Follicular Lymphoma Compared to Those with Transformed Non-Hodgkin Lymphoma: A Population-Based Comparative Study.

Improved Survival in Red Blood Cell Transfusion Dependent Patients with Primary Myelofibrosis (PMF) Receiving Iron Chelation Therapy.

Improved Leukemia-Free and Overall Survival in Patients with Myelodysplastic Syndrome Receiving Iron Chelation Therapy: A Subgroup Analysis.

Transfusion Dependence in Patients with Primary Myelofibrosis Has a Negative Impact on Survival Independent of Decreased Myelopoiesis.

Myeloablative Allogeneic Stem Cell Transplantation for Relapsed Composite Low and Intermediate Grade Lymphoma Is Not Superior to Autologous Stem Cell Transplantation - Reduced Relapse Risk Is Offset by Higher Treatment Related Mortality.

Long Term Results of Myeloablative Allogeneic Stem Cell Transplantation Using Related and Unrelated Donors in Patients with Relapsed Composite Low and Intermediate Grade (Including Transformed) Lymphoma.

Prior Rituximab Reduces Relapse and Improves Survival Following High Dose Chemotherapy and Stem Cell Transplantation for Relapsed Composite Low and Intermediate Grade (Including Transformed) Lymphoma.

Long Term Follow-Up Results for Patients with Hodgkin Lymphoma after First Remission of Longer Than Ten Years: A Population Based Study of 954 Patients from the British Columbia Cancer Agency.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only